Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 84.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,960 shares of the biopharmaceutical company's stock after selling 536,367 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.11% of Ultragenyx Pharmaceutical worth $5,442,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in RARE. UMB Bank n.a. lifted its stake in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 352 shares during the period. Arizona State Retirement System lifted its position in shares of Ultragenyx Pharmaceutical by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company's stock valued at $853,000 after acquiring an additional 434 shares during the period. KBC Group NV lifted its position in shares of Ultragenyx Pharmaceutical by 24.5% during the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock valued at $143,000 after acquiring an additional 506 shares during the period. Amalgamated Bank boosted its stake in shares of Ultragenyx Pharmaceutical by 13.4% during the 2nd quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company's stock worth $242,000 after acquiring an additional 696 shares in the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $43,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of research analyst reports. TD Cowen boosted their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Canaccord Genuity Group reiterated a "buy" rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. JPMorgan Chase & Co. dropped their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, HC Wainwright raised their price objective on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $87.46.

Ultragenyx Pharmaceutical Trading Up 4.3 %

Shares of Ultragenyx Pharmaceutical stock traded up $2.04 during trading hours on Friday, reaching $49.38. 815,449 shares of the company's stock were exchanged, compared to its average volume of 654,509. Ultragenyx Pharmaceutical Inc. has a 52-week low of $37.02 and a 52-week high of $60.37. The company has a fifty day moving average of $51.17 and a 200-day moving average of $48.82. The firm has a market capitalization of $4.56 billion, a price-to-earnings ratio of -7.63 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company's quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.23) earnings per share. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.80% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.